Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DaVita HealthCare Partner (NY:DVA)

141.55 +0.01 (+0.01%)
Official Closing Price Updated: 4:10 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DaVita HealthCare Partner

< Previous 1 2 3 4 5 6 7 8 Next >
3 Top-Rated Stocks To Buy After Comfortably Surpassing Earnings Expectations
This week’s earnings lineup has featured several top-rated stocks that have added to this optimistic growth narrative and here are a few to consider 
Via Talk Markets
Why DaVita Stock Popped Today
The dialysis services company handily beat expectations with its latest quarter. 
Via The Motley Fool
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
DaVita (DVA) Q4 2023 Earnings Call Transcript
DVA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
DaVita: Q4 Earnings Insights
Via Benzinga
DaVita Earnings Preview
Via Benzinga
In-Depth Technical Analysis of DAVITA INC.
DAVITA INC (NYSE:DVA) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
Bull of the Day: DaVita
Most anybody who works in healthcare is familiar with the company and its services which include 2,707 outpatient centers in 46 states, as well as 351 centers in 11 countries worldwide. 
Via Talk Markets
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
DaVita: Q3 Earnings Insights
Via Benzinga
Time To Buy These High Growth Stocks As Earnings Approach
This week’s earnings lineup will be highlighted by several growth stocks with none standing out more than Airbnb and DaVita 
Via Talk Markets
Meet the Most Ridiculously Cheap Stock in Warren Buffett's Berkshire Hathaway Portfolio
This stock isn't cheap because it's performed poorly over the past 12 months. 
Via The Motley Fool
2 Best Warren Buffett Stocks to Buy for the Long Haul
You don't need to have millions of dollars to invest in quality businesses. 
Via The Motley Fool
Earn a 5.79% Dividend Yield from DaVita Stock Using This Hack
Via Benzinga
Don't Overlook These Top Value Stocks In January It's Time To Buy
Investors searching for value will want to pay attention to a few top-rated stocks that are standing out among the finance and medical sectors 
Via Talk Markets
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
5 Undervalued Stocks In The S&P 500 ETF To Buy For 2024
After several twists and turns, the S&P 500 has hit a series of new 2023 highs lately, driven by the optimism that the Fed is done with interest rate hikes. 
Via Talk Markets
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
The stock market is such a well-oiled, wealth-generating machine that investors can start with just $100 to buy these no-brainer stocks. 
Via InvestorPlace
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
DaVita (DVA) Q3 2023 Earnings Call Transcript
DVA earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
Buffett’s Bullish Bets: 3 Stocks Where Warren Has At Least a 25% Stake
A man who likes to make big bets on businesses, these Warren Buffett stocks are his biggest ones without actually owning the business. 
Via InvestorPlace
3 Stocks to Buy From the ‘Buy the Dip’ ETF
It’s a lot harder than it looks to buy the dip. Using artificial intelligence to do this makes these three stocks a buy. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review
The major indexes stalled at key levels amid weak breadth. 
Via Investor's Business Daily
Novo Nordisk's Kidney Outcomes Trial Has Broad Industry Implications
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in... 
Via Benzinga
Why Dialysis Stocks Plunged Today
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here's what investors need to know. 
Via The Motley Fool
Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%
Ozempic may be able to treat kidney disease. This news has sent competitor DaVita into a tailspin as DVA stock plunges. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.